Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Allosteric changes in HDM2 by the ATM phosphomimetic S395D mutation: implications on HDM2 function

L. Uhrik, L. Wang, L. Haronikova, I. Medina-Medina, Y. Rebolloso-Gomez, S. Chen, B. Vojtesek, R. Fahraeus, L. Hernychova, V. Olivares-Illana,

. 2019 ; 476 (21) : 3401-3411. [pub] 20191115

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025494

Allosteric changes imposed by post-translational modifications regulate and differentiate the functions of proteins with intrinsic disorder regions. HDM2 is a hub protein with a large interactome and with different cellular functions. It is best known for its regulation of the p53 tumour suppressor. Under normal cellular conditions, HDM2 ubiquitinates and degrades p53 by the 26S proteasome but after DNA damage, HDM2 switches from a negative to a positive regulator of p53 by binding to p53 mRNA to promote translation of the p53 mRNA. This change in activity is governed by the ataxia telangiectasia mutated kinase via phosphorylation on serine 395 and is mimicked by the S395D phosphomimetic mutant. Here we have used different approaches to show that this event is accompanied by a specific change in the HDM2 structure that affects the HDM2 interactome, such as the N-termini HDM2-p53 protein-protein interaction. These data will give a better understanding of how HDM2 switches from a negative to a positive regulator of p53 and gain new insights into the control of the HDM2 structure and its interactome under different cellular conditions and help identify interphases as potential targets for new drug developments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025494
003      
CZ-PrNML
005      
20201222153929.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1042/BCJ20190687 $2 doi
035    __
$a (PubMed)31652301
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Uhrik, Lukas $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
245    10
$a Allosteric changes in HDM2 by the ATM phosphomimetic S395D mutation: implications on HDM2 function / $c L. Uhrik, L. Wang, L. Haronikova, I. Medina-Medina, Y. Rebolloso-Gomez, S. Chen, B. Vojtesek, R. Fahraeus, L. Hernychova, V. Olivares-Illana,
520    9_
$a Allosteric changes imposed by post-translational modifications regulate and differentiate the functions of proteins with intrinsic disorder regions. HDM2 is a hub protein with a large interactome and with different cellular functions. It is best known for its regulation of the p53 tumour suppressor. Under normal cellular conditions, HDM2 ubiquitinates and degrades p53 by the 26S proteasome but after DNA damage, HDM2 switches from a negative to a positive regulator of p53 by binding to p53 mRNA to promote translation of the p53 mRNA. This change in activity is governed by the ataxia telangiectasia mutated kinase via phosphorylation on serine 395 and is mimicked by the S395D phosphomimetic mutant. Here we have used different approaches to show that this event is accompanied by a specific change in the HDM2 structure that affects the HDM2 interactome, such as the N-termini HDM2-p53 protein-protein interaction. These data will give a better understanding of how HDM2 switches from a negative to a positive regulator of p53 and gain new insights into the control of the HDM2 structure and its interactome under different cellular conditions and help identify interphases as potential targets for new drug developments.
650    _2
$a alosterická regulace $7 D000494
650    _2
$a aminokyselinové motivy $7 D020816
650    _2
$a ATM protein $x genetika $x metabolismus $7 D064007
650    _2
$a lidé $7 D006801
650    12
$a missense mutace $7 D020125
650    _2
$a fosforylace $7 D010766
650    _2
$a vazba proteinů $7 D011485
650    _2
$a protoonkogenní proteiny c-mdm2 $x chemie $x genetika $x metabolismus $7 D051736
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wang, Lixiao $u Department of Medical Biosciences, Umeå University, SE-90185 Umeå, Sweden.
700    1_
$a Haronikova, Lucia $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Medina-Medina, Ixaura $u Laboratorio de Interacciones Biomoleculares y Cáncer, Instituto de Física Universidad Autónoma de San Luis Potosí, Zona Universitaria, Manuel Nava 6, 78290 San Luis Potosí, México.
700    1_
$a Rebolloso-Gomez, Yolanda $u Laboratorio de Interacciones Biomoleculares y Cáncer, Instituto de Física Universidad Autónoma de San Luis Potosí, Zona Universitaria, Manuel Nava 6, 78290 San Luis Potosí, México.
700    1_
$a Chen, Sa $u Department of Medical Biosciences, Umeå University, SE-90185 Umeå, Sweden.
700    1_
$a Vojtesek, Borivoj $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Fahraeus, Robin $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic. Department of Medical Biosciences, Umeå University, SE-90185 Umeå, Sweden. Équipe Labellisée Ligue Contre le Cancer, INSERM UMR 1162, Université Paris 7, 27 Rue Juliette Dodu, 75010 Paris, France.
700    1_
$a Hernychova, Lenka $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
700    1_
$a Olivares-Illana, Vanesa $u Laboratorio de Interacciones Biomoleculares y Cáncer, Instituto de Física Universidad Autónoma de San Luis Potosí, Zona Universitaria, Manuel Nava 6, 78290 San Luis Potosí, México.
773    0_
$w MED00009308 $t The Biochemical journal $x 1470-8728 $g Roč. 476, č. 21 (2019), s. 3401-3411
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31652301 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153924 $b ABA008
999    __
$a ok $b bmc $g 1599639 $s 1116180
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 476 $c 21 $d 3401-3411 $e 20191115 $i 1470-8728 $m Biochemical journal (London. 1984) $n Biochem J $x MED00009308
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace